A Trial of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours
Status:
Unknown status
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
To investigate safety, tolerability and pharmacokinetics of C-met Kinase Inhibitor HS-10241
in Subjects With Advanced Solid Tumours that are not eligible for conventional or intensive
treatment. The dose of HS-10241 will be escalated to determine the dose limiting toxicity
(DLT) and the maximum tolerated dose (MTD) of HS-10241 in advanced cancer patients. At the
same time, pharmacokinetic characteristics and preliminary efficacy of HS-10241 will be
observed in advanced cancer patients. To determine the recommended dosage regimen for phase
II.